Antibodies

30 Jun 2017 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab)
29 Jun 2017 GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
27 Jun 2017 MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers
27 Jun 2017 GSK starts phase III study with mepolizumab in patients with nasal polyps
27 Jun 2017 Ablynx achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA
27 Jun 2017 ImmunoGen Presents Data from Phase I Study of IMGN779 in Acute Myeloid Leukemia
27 Jun 2017 Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Hemopoietic Cell Transplantation From Matched Unrelated Donors Strongly Support the Use of Grafalon® (Anti-Human-T-Lymphocyte Immunoglobulin) as Standard Therapy
27 Jun 2017 Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
27 Jun 2017 Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
27 Jun 2017 Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases
26 Jun 2017 Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1 And HAVEN 2) in Hemophilia A With Inhibitors
26 Jun 2017 Ablynx initiates a single and multiple dose phase I study of caplacizumab in healthy Japanese subjects
25 Jun 2017 Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial
23 Jun 2017 Alexion Receives Positive CHMP Opinion for Soliris(R) (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union
23 Jun 2017 FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers
23 Jun 2017 Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
22 Jun 2017 Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
21 Jun 2017 Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
21 Jun 2017 GeNeuro Announces First Patient Treated in Phase 2a Study with GNbAC1 in Type 1 Diabetes
21 Jun 2017 Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma
21 Jun 2017 FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
21 Jun 2017 Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
20 Jun 2017 Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
19 Jun 2017 Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
17 Jun 2017 MacroGenics Presents Updated Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2017)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top